Top

Published in:

01-01-2015 | Editorial

Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis

Authors: Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Published in: Digestive Diseases and Sciences | Issue 1/2015

Excerpt

Nonalcoholic fatty liver disease (NAFLD) is an ever-growing problem in the developed and developing worlds, affecting 15–40 % of the population [1]. Once regarded as a benign condition, NAFLD is the leading cause of cryptogenic cirrhosis and cryptogenic hepatocellular carcinoma (HCC) [2], and the third most frequent indication for liver transplantation [3]. …

Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61:409–415.PubMedCrossRef

Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974.PubMedCrossRef

Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.PubMedCrossRef

Chan HL, de Silva HJ, Leung NW, et al. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol. 2007;22:801–808.PubMedCrossRef

Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007;11:173–189, x.

Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.PubMedCrossRef

Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462.PubMedCrossRef

Wong GL. Transient elastography: kill two birds with one stone? World J Hepatol. 2013;5:264–274.PubMedCentralPubMedCrossRef

Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.PubMedCrossRef

10.

de Ledinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918.PubMedCrossRef

11.

Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.PubMedCrossRef

12.

Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012;19:244–253.PubMedCrossRef

13.

Cardoso AC, Sasso M, Miette V, et al. Controlled attenuation parameter: a novel FibroScan-based tool to detect and quantify steatosis in chronic hepatitis B. http://onlinelibrary.wiley.com.easyaccess1.lib.cuhk.edu.hk/doi/10.1002/hep.23974/pdf.

14.

Beaugrand M, de Ledinghen V, Douvin C, et al. Validation of controlled attenuation parameter (CAP) as a non-invasive marker of steatosis in 228 patients with chronic liver disease from various causes. J Hepatol. 2010;52:S35–S36.

15.

Beaugrand M, Ziol M, de Ledinghen V, et al. Controlled attenuation parameter: A novel FibroScan^®-based tool to detect and quantify steatosis. Preliminary study in patient with alcoholoc and non alcoholic fatty liver disease. J Hepatol. 2010;52:S158–S159.

16.

Chon YE, Jung KS, Kim KJ, et al. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3293-1.

17.

Mi YQ, Shi QY, Zu L, et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan(^®): validation in chronic hepatitis B. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3341-x.

18.

Wong GL, Wong VW, Choi PC, et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2009;24:1002–1007.PubMedCrossRef

19.

Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16:36–44.PubMedCrossRef

20.

Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540.PubMedCrossRef

21.

Wong GL, Chan HL, Yu Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883–893.PubMedCrossRef

22.

Wong GL, Wong VW, Choi PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111–117.PubMedCrossRef

23.

Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–345.PubMedCrossRef

Title: Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis
Authors: Grace Lai-Hung Wong
Vincent Wai-Sun Wong
Publication date: 01-01-2015
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 1/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-014-3429-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Effects of Age at Disease Onset and at Treatment on Serology in Inflammatory Bowel Diseases

Endoclips to Facilitate Cannulation and Sphincterotomy During ERCP in a Patient with an Ampulla Within a Large Duodenal Diverticulum: Case Report and Literature Review

Decreases in Activated CD8+ T Cells in Patients with Severe Hepatitis B Are Related to Outcomes

Is Less More: Does Leukopenia Predict Remission in Patients with Inflammatory Bowel Disease Receiving Thiopurine Treatment?

Transenteral Bowel Preparation for Colonoscopy Is More Comfortable than the Traditional Method with No Inferiority in Efficacy

Probability of High-Risk Colorectal Neoplasm Recurrence Based on the Results of Two Previous Colonoscopies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page